These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 21321089)

  • 1. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01).
    Barlesi F; Gervais R; Lena H; Hureaux J; Berard H; Paillotin D; Bota S; Monnet I; Chajara A; Robinet G
    Ann Oncol; 2011 Nov; 22(11):2466-2470. PubMed ID: 21321089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial.
    Dinglin XX; Huang Y; Liu H; Zeng YD; Hou X; Chen LK
    J Neurooncol; 2013 May; 112(3):461-6. PubMed ID: 23420398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.
    Shepherd FA; Dancey J; Arnold A; Neville A; Rusthoven J; Johnson RD; Fisher B; Eisenhauer E
    Cancer; 2001 Aug; 92(3):595-600. PubMed ID: 11505404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer.
    Schuette WH; Gröschel A; Sebastian M; Andreas S; Müller T; Schneller F; Guetz S; Eschbach C; Bohnet S; Leschinger MI; Reck M
    Clin Lung Cancer; 2013 May; 14(3):215-23. PubMed ID: 23332288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Pujol JL; Paz-Ares L; de Marinis F; Dediu M; Thomas M; Bidoli P; Corral J; San Antonio B; Chouaki N; John W; Zimmermann A; Visseren-Grul C; Gridelli C
    Clin Lung Cancer; 2014 Nov; 15(6):418-25. PubMed ID: 25104617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A randomized, controlled, multicenter clinical trial comparing pemetrexed/cisplatin and gemcitabine/cisplatin as first-line treatment for advanced nonsquamous non-small cell lung cancer].
    Huang Y; Liu Y; Zhou J; Xu N; Li B; Wu G; Fang J; Li K; Liu X; Liu W; Lu Y; Wang M; Liu W; Liang H; Zhang Y; Huang C; Wang S; Wang Y; Yu S; Chang J; Wang Z; Hu Z; Zhang L
    Zhongguo Fei Ai Za Zhi; 2012 Oct; 15(10):576-82. PubMed ID: 23075681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
    Paz-Ares LG; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    J Clin Oncol; 2013 Aug; 31(23):2895-902. PubMed ID: 23835707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral vinorelbine plus cisplatin as first-line chemotherapy in nonsquamous non-small-cell lung cancer: final results of an International randomized phase II study (NAVotrial 01).
    Bennouna J; Havel L; Krzakowski M; Kollmeier J; Gervais R; Dansin E; Serke M; Favaretto A; Szczesna A; Cobo M; Ciuffreda L; Jassem J; Nicolini M; Ramlau R; Amoroso D; Melotti B; Almodovar T; Riggi M; Caux NR; Vaissière N; Tan EH
    Clin Lung Cancer; 2014 Jul; 15(4):258-65. PubMed ID: 24954228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
    Scagliotti GV; Parikh P; von Pawel J; Biesma B; Vansteenkiste J; Manegold C; Serwatowski P; Gatzemeier U; Digumarti R; Zukin M; Lee JS; Mellemgaard A; Park K; Patil S; Rolski J; Goksel T; de Marinis F; Simms L; Sugarman KP; Gandara D
    J Clin Oncol; 2008 Jul; 26(21):3543-51. PubMed ID: 18506025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer.
    Ortuzar W; Hanna N; Pennella E; Peng G; Langer C; Monberg M; Scagliotti G
    Clin Lung Cancer; 2012 Jan; 13(1):24-30. PubMed ID: 21831719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of High-Dose Pemetrexed Plus Cisplatin as First-Line Chemotherapy In the Treatment of Patients with Brain Metastases from Lung Adenocarcinoma.
    He Q; Wang Y; Zou P; Wang Y; Xiu C; Zhang H; Chi N; Zou H; Xu J; Zhou S; Tao R
    World Neurosurg; 2017 Mar; 99():758-762. PubMed ID: 27060518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.
    Gadgeel SM; Ruckdeschel JC; Patel BB; Wozniak A; Konski A; Valdivieso M; Hackstock D; Chen W; Belzer K; Burger AM; Marquette L; Turrisi A
    J Thorac Oncol; 2011 May; 6(5):927-33. PubMed ID: 21415776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquamous non-small cell lung cancer.
    Schmid-Bindert G; Gebbia V; Mayer F; Arriola E; Márquez-Medina D; Syrigos K; Biesma B; Leschinger MI; Frimodt-Moller B; Ripoche V; Myrand SP; Nguyen TS; Hozak RR; Zimmermann A; Visseren-Grul C; Schuette W
    Lung Cancer; 2013 Sep; 81(3):428-434. PubMed ID: 23790468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.
    Kreuter M; Vansteenkiste J; Fischer JR; Eberhardt W; Zabeck H; Kollmeier J; Serke M; Frickhofen N; Reck M; Engel-Riedel W; Neumann S; Thomeer M; Schumann C; De Leyn P; Graeter T; Stamatis G; Zuna I; Griesinger F; Thomas M;
    Ann Oncol; 2013 Apr; 24(4):986-92. PubMed ID: 23161898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2.
    Zukin M; Barrios CH; Pereira JR; Ribeiro Rde A; Beato CA; do Nascimento YN; Murad A; Franke FA; Precivale M; Araujo LH; Baldotto CS; Vieira FM; Small IA; Ferreira CG; Lilenbaum RC
    J Clin Oncol; 2013 Aug; 31(23):2849-53. PubMed ID: 23775961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer.
    Mornex F; Peignaux K; Germain T; Wautot V; Chouaki N; Bourayou N; Tourani JM
    Lung Cancer; 2013 Apr; 80(1):68-74. PubMed ID: 23332163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.
    Patel JD; Hensing TA; Rademaker A; Hart EM; Blum MG; Milton DT; Bonomi PD
    J Clin Oncol; 2009 Jul; 27(20):3284-9. PubMed ID: 19433684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.
    Scagliotti GV; Gridelli C; de Marinis F; Thomas M; Dediu M; Pujol JL; Manegold C; San Antonio B; Peterson PM; John W; Chouaki N; Visseren-Grul C; Paz-Ares LG
    Lung Cancer; 2014 Sep; 85(3):408-14. PubMed ID: 25088661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer -- a retrospective analysis].
    Yamaguchi T; Nakanishi T; Hayashi M; Uozu S; Okamura T; Morishita M; Takeyama T; Minezawa T; Morikawa S; Niwa Y; Mieno Y; Kato A; Hoshino T; Isogai S; Okazawa M; Imaizumi K
    Gan To Kagaku Ryoho; 2015 Feb; 42(2):183-7. PubMed ID: 25743136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.